Status:

COMPLETED

Effects of Ghrelin on the Sleep-EEG and Nocturnal Secretion of Hormones

Lead Sponsor:

Max-Planck-Institute of Psychiatry

Collaborating Sponsors:

German Research Foundation

Conditions:

Healthy

Major Depression

Eligibility:

All Genders

20-70 years

Phase:

NA

Brief Summary

Ghrelin, an acylated peptide consisting of 28 amino acids, is the endogenous ligand of the growth hormone secretagogue receptor (GHS-R). It is synthesized predominantly in the stomach but has been als...

Eligibility Criteria

Inclusion

  • Healthy females and males
  • Male and female patients with major depression

Exclusion

  • Life time or family history of psychiatric or neurological disorders
  • Sleep disturbances
  • Shift work
  • Any current disease
  • Any medication
  • Long distance flight within 3 months prior to study entry
  • Smoking
  • Any medication during the week prior to study entry
  • Any current disease other than major depression

Key Trial Info

Start Date :

March 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 1 2007

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT00447512

Start Date

March 1 2004

End Date

October 1 2007

Last Update

October 31 2007

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Max Planck Institute of Psychiatry

Munich, Germany, 80804

Effects of Ghrelin on the Sleep-EEG and Nocturnal Secretion of Hormones | DecenTrialz